Abivax SA American Depositary Shares (NASDAQ:ABVX) — Market Cap & Net Worth
Market Cap & Net Worth: Abivax SA American Depositary Shares (ABVX)
Abivax SA American Depositary Shares (NASDAQ:ABVX) has a market capitalization of $10.93 Billion ($10.93 Billion) as of August 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2103 globally and #785 in its home market, demonstrating a 0.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abivax SA American Depositary Shares's stock price $125.39 by its total outstanding shares 87160669 (87.16 Million). Review ABVX total debt and obligations to assess the company's total debt and financial obligations.
Abivax SA American Depositary Shares Market Cap History: 2023 to 2026
Abivax SA American Depositary Shares's market capitalization history from 2023 to 2026. Data shows growth from $932.62 Million to $10.93 Billion (134.20% CAGR).
Index Memberships
Abivax SA American Depositary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.44% | #40 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.03% | #238 of 3165 |
Weight: Abivax SA American Depositary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abivax SA American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abivax SA American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
59.12x
Abivax SA American Depositary Shares's market cap is 59.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $932.62 Million | $4.62 Million | -$147.74 Million | 201.82x | N/A |
| 2024 | $638.02 Million | $10.79 Million | -$176.24 Million | 59.12x | N/A |
Competitor Companies of ABVX by Market Capitalization
Companies near Abivax SA American Depositary Shares in the global market cap rankings as of August 6, 2026.
Key companies related to Abivax SA American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Abivax SA American Depositary Shares Historical Marketcap From 2023 to 2026
Between 2023 and today, Abivax SA American Depositary Shares's market cap moved from $932.62 Million to $ 10.93 Billion, with a yearly change of 134.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.93 Billion | -7.02% |
| 2025 | $11.75 Billion | +1742.28% |
| 2024 | $638.02 Million | -31.59% |
| 2023 | $932.62 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Abivax SA American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.93 Billion USD |
| MoneyControl | $10.93 Billion USD |
| MarketWatch | $10.93 Billion USD |
| marketcap.company | $10.93 Billion USD |
| Reuters | $10.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more